Exploring the Impact of GLP-1 Receptor Agonists on Musculoskeletal Health in Surgical Patients

The Role of GLP-1 Receptor Agonists in Orthopaedic Surgery

The evolution of pharmacotherapy for obesity and Type 2 diabetes has highlighted the rapid adoption of glucagon-like peptide-1 receptor agonists (GLP-1 RAs). Notable among these medications is semaglutide, which has gained significant traction due to its efficacy in glycemic management, weight reduction, and cardiovascular health improvement. However, emerging research presented at the 2026 Annual Meeting of the American Academy of Orthopaedic Surgeons has prompted further examination of how GLP-1 RAs may influence musculoskeletal health, particularly in the context of surgical outcomes.

Research Findings on GLP-1 RAs

Impact on Postoperative Recovery

Research led by medical students from prominent institutions has revealed a correlation between GLP-1 RA usage and improved short-term postoperative outcomes. A cohort study analyzed data from patients with obesity undergoing common orthopaedic procedures from 2010 to 2023. This retrospective analysis indicated that patients utilizing GLP-1 RAs experienced significantly lower rates of postoperative complications, including reduced emergency department visits and surgical site infections, particularly in total knee arthroplasty (TKA) and total hip arthroplasty (THA).

Interestingly, while GLP-1 RAs showed an association with favorable recovery rates post-surgery, the literature on long-term effects remains limited. Investigators underscored the importance of longitudinal follow-up data as trends in GLP-1 RA adoption soar.

Increased Long-Term Risks

Despite the encouraging findings regarding postoperative recovery, researchers also highlighted alarming evidence regarding the long-term health risks associated with the continued use of GLP-1 RAs. A separate retrospective cohort study found that patients treated with GLP-1 agonists exhibited a notably increased risk of osteoporosis, gout, and osteomalacia after five years, raising concerns about potential adverse effects on bone health among these patients.

Data revealed that patients relying on GLP-1 RAs exhibited a 1.29-fold higher risk of developing osteoporosis compared to matched controls, as well as elevated rates of gout and a significant increase in the incidence of osteomalacia. These findings point to a critical need for healthcare providers to conduct bone health surveillance in populations at risk, particularly those with preexisting conditions such as chronic kidney disease or rheumatoid arthritis.

Conclusion and Clinical Implications

The latest studies stress the dual nature of GLP-1 receptor agonists: while they offer clear immediate benefits in surgical recovery for obese patients, they may carry concerning risks regarding musculoskeletal health. Clinicians prescribing GLP-1 RAs must balance these factors carefully and consider ongoing monitoring for complications associated with long-term use.

In light of these developments, it becomes paramount to foster a deeper understanding of how such an expedient adoption of GLP-1 medications may affect practice patterns in orthopaedics and pave the way for future research. Addressing the intricate balance between therapeutic benefits and potential risks will undoubtedly define the trajectory of GLP-1 RAs in musculoskeletal care going forward.